染色体微阵列作为基于人群的早孕期联合筛查高风险妊娠的一线诊断基因组工具
该回顾性研究纳入575例因早孕期联合筛查风险≥1:300而接受侵入性检测的连续妊娠,以染色体微阵列(CMA)为标准诊断方法。CMA总检出率8.9%(95%CI 6.8-11.5%),显著高于传统细胞遗传学分析的估计值6.8%(95%CI 5.0-9.1%)(P=0.0049)。将侵入性检测风险阈值降至1/100或1/50,分别会导致60%或100%的致病性拷贝数变异被漏诊。
要点
- CMA在cFTS高风险妊娠中总检出率8.9%,高于传统细胞遗传学估计的6.8%(P=0.0049)。
- CMA检出22例21/18/13三体、14例其他非整倍体和15例致病/可能致病CNV。
- 阈值降至1/100或1/50,分别会漏诊60%或100%的致病性CNV。
核心结论
- CMA是一种有价值的诊断技术,可在cFTS高风险妊娠中识别更多基因组异常。
- 将诊断检测限制在风险高于1/100或1/50的妊娠(如条件性NIPT/侵入性检测模型所提议),会导致相当比例的致病性CNV在早孕期筛查中被漏诊。
研究设计与样本
- 回顾性研究,纳入2015年9月至2016年9月期间在丹麦中部和北部地区 publicly funded 基于人群的筛查项目中因cFTS风险≥1:300而接受侵入性检测的575例连续妊娠。
- 排除胎儿颈项透明层厚度≥3.5 mm或选择无创产前检测(NIPT)的孕妇。
- 采用180-K寡核苷酸阵列对直接从绒毛膜绒毛/羊膜腔穿刺样本提取的DNA进行比较基因组杂交。
主要发现
- 575例侵入性检测妊娠中,CMA检出22例(3.8%(95%CI 2.5-5.7%))21、18、13三体。
- 检出14例(2.4%(95%CI 1.4-4.0%))其他类型非整倍体。
- 检出15例(2.6%(95%CI 1.5-4.3%))致病或可能致病CNV;其中3例>10 Mb可能被染色体分析检出,其余12例最可能不被传统细胞遗传学技术检出。
- CMA总检出率8.9%(95%CI 6.8-11.5%)显著高于传统细胞遗传学分析的估计值6.8%(95%CI 5.0-9.1%)(P=0.0049)。
- 将侵入性诊断检测的cFTS风险阈值降至1/100或1/50,分别会导致60%或100%的致病性CNV被漏诊。
临床怎么用
- 原文结论认为CMA是一种有价值的诊断技术,可在cFTS高风险妊娠中识别更多基因组异常。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the performance of high-resolution chromosomal microarray (CMA) as the standard diagnostic approach for genomic imbalances in pregnancies with increased risk based on combined first-trimester screening (cFTS). METHODS: This was a retrospective study of genomic findings in a cohort of 575 consecutive pregnancies undergoing invasive testing because of a cFTS risk ≥ 1:300 on a publicly funded population-based screening program in the Central and Northern Regions of Denmark, between September 2015 and September 2016. Women with fetal nuchal translucency thickness ≥ 3.5 mm or opting for non-invasive prenatal testing (NIPT) were excluded. Comparative genomic hybridization was performed using a 180-K oligonucleotide array on DNA extracted directly from chorionic villus/amniocentesis samples. Genomic outcomes were reported in relation to cFTS findings. RESULTS: Of the 575 pregnancies that underwent invasive testing, CMA detected 22 (3.8% (95% CI, 2.5-5.7%)) cases of trisomies 21, 18 and 13, 14 (2.4% (95% CI, 1.4-4.0%)) cases of other types of aneuploidy and 15 (2.6% (95% CI, 1.5-4.3%)) cases with a pathogenic or probably pathogenic copy number variant (CNV). Of the 15 CNVs, three were > 10 Mb and would probably have been detected by chromosomal analysis, but the other 12 would most probably not have been detected using conventional cytogenetic techniques; therefore, the overall detection rate of CMA (8.9% (95% CI, 6.8-11.5%)) was significantly higher than that estimated for conventional cytogenetic analysis (6.8% (95% CI, 5.0-9.1%)) (P = 0.0049). Reducing the cFTS risk threshold for invasive diagnostic testing to 1 in 100 or 1 in 50 would have led, respectively, to 60% or 100% of the pathogenic CNVs being missed. CONCLUSIONS: CMA is a valuable diagnostic technique that can identify an increased number of genomic aberrations in pregnancies at increased risk on cFTS. Limiting diagnostic testing to pregnancies with a risk above 1 in 100 or 1 in 50, as proposed in contingent NIPT/invasive testing models, would lead to a significant proportion of pathogenic CNVs being missed at first-trimester screening. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Vogel I, Petersen OB, Christensen R, et al. Chromosomal microarray as primary diagnostic genomic tool for pregnancies at increased risk within a population-based combined first-trimester screening program. Ultrasound Obstet Gynecol. 2018. PMID: 28608362. doi:10.1002/uog.17548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。